Member Info for Cliostock

Likewise Ody I am tired of hearing how far ahead of schedule Axis launched and how the strategy was adapted for covid. Sure, that earned SA some chips, but those chips have now been cashed and the board have to look to the future for brownie points rather than looking to the past.

I also agree that getting momentum back is key. There has been opportunities for this that have been missed. For example the oral study, we were told the paper would be written and released within about 90 days after the completion of the study. Have we not heard anything because the findings were not RNS-worthy? If not why say they were happy with the results? If there had been an RNS with some details of the findings, a bit about the potential of the products/science and a statement that it will be worked on in the background but Axis/Skinbiotix is the current focus, they could have pushed anything related to oral back a good while but the market would have been happy with the news and it would assist with momentum. Instead it seems to have been pushed back with no news, and the market has really punished the uncertainty here.

For what it’s worth about SA, I do believe he will pull something off. I think he has the skills needed to do what we need him to do. It would just be more pleasant for shareholders if he showed us some results sooner rather than later.

Ody I also look forward to those three updates. I think regarding PE, we are in the transition period between being a pre-revenue entity with some valuable IP, to a commercial business without a big pot of cash to do it with. I think that explains the reason the PE valuation looks unusual at the moment.

You have a point about the lack of news and updates over the past year or so. SA has promised to work on this but we haven’t seen much yet to show he means what he said. Hopefully this will come good. We do have to understand there is a limited amount he can say and hopefully he is pushing in the background to open up the news. It is after all important for the share price of his own and our business.

I think there is a plan of action going on which seems very well considered - that’s not to say SA has shown he is capable of pulling it off. Is he one of those people that can talk a good game but can’t deliver when push comes to shove? I sincerely hope not.

Ody when you comment it’s like reading thoughts and opinions from someone that is living six months behind everyone else. Is your internet slow?

Like most on here I’m all for sensible discussion of the negatives/concerns - but you take a totally one sided viewpoint, completely leaving out points which address what you are saying. Time to send AOL your notice and get broadband I think.

Toyin he means if Stuart pulls the strategies off we’ll owe him a pint and if he doesn’t he’ll owe us a drink whilst explaining why the targets have been missed. This would take place at the end of 2023 if the targeted strategies have not been executed during the year.

If the strategies are the right ones, we should have 3 respectable revenue streams within 2023 plus others in development, which I am confident will yield a 75p plus SP even in this economy. If we have another soft launch which disappoints the market the SP will be held back and then you would have to question if the commercial strategies are the right ones if they are underperforming. I’d say our CEO is very much in control of making sure we’re pursuing the right strategies.

However in the interests of balance, I will say I won’t be buying our CEO a beer for a 4p rise in SP after witnessing the free fall from 75p. I’ll consider it when the talk turns to walk and one or two of the commercial strategies have come off, restoring the SP back to the 75p level or above.

It certainly is a good thing that we have a share price rise and investors that know the company inside out aren’t sure which of 3 different things could be behind the uplift.

Totally agree TC.

There is absolutely no doubt Skinbiotix will be launched before Sweetbiotix!

You’re right Aquae what Ody is saying is not accurate, it’s the standard troll drivel of pretending they don’t know things that work against their agenda. Ody knows EXACTLY why the £1.2m target was withdrawn, but as he has probably already sold out and lost his money, he doesn’t want to see any LTH’s or new investors making the gains we’ve seen over the last two days, hence the reappearance. They need counselling not a LSE BB.

£70k sales is certainly disappointing Ody, hence the SP being at 16p.

We know we are expecting news soon on Croda, we should hear at some point about the acquisition that prompted the raise and despite the slow start of the first Axis product we can reasonably expect the company to be improving their methods and increasing sales. The Axis pillar holds potential for a formulated Acne product and a future deal with a multinational. There are 4 or 5 more potential income sources but as they are longer term I won’t go mad and focus on them here. I believe the SP lift we have seen today is a result of calculated investors buying at the ‘70k revenue price’, waiting for the ‘multiple sources of income price’.

If we have launched in Spain/Portugal it should absolutely be RNS’d. Regardless of orders received it’s material information, if only to confirm that the previously RNS’d statement about launch by year end has been achieved. I’ve always thought the old line about ‘not being a company that RNS’d the opening of an envelope’ was nonsense. If our team have pulled off a product approval and launch into new territories, I’d rather the market know about it, rather than assume it’s another disappointment. Well done to SA and the team, if we in fact have launched.

Scientific evidence certainly is out there and it’s very easy to find, but that wouldn’t suit Oleric’s agenda, he would prefer to try and sew the seed of doubt for some reason. I’d be more inclined to help if there was ever any recognition of the proven facts.

For others reading, not only is there an abundance of bedtime reading out there about Skinbiotix, but the real golden bullet in our ****nal is that our lysate can make specific claims for anti-aging amongst other things. A product containing Matrixyl has to say ‘**we are selling this as an anti aging cream because 37 out of 49 people surveyed said their skin looked younger after using this cream’. Products containing Skinbiotix will be able to say ‘this is scientifically proven to be anti aging’. It’s all about marketing and the easier a product is to market the more it will sell. It’s easy to see why Croda want to run the product alongside Matrixyl. It enhances their product portfolio and stops a competitor getting their hands on it.

Say what you wish about the SP and the Axis launch and SA missing goals, chances are I’ll agree with you, but you’d have to be the village idiot not to see Skinbiotix is good science. It’s comforting to know Croda are launching it because this is their bread and butter, it’s not ‘sector blurring’ or ‘trailblazing’ it should be fairly procedural for them.

Hi Bel, I can sort of see what you are getting at, I think it might be a bit of a rabbit hole and with any luck it won’t be too far into 2023 before it all gets cleared up. It’s probably wishful thinking to expect something straight after SA’s meeting with the Croda commercial representatives, but hopefully there will be something to say in the first 6 months of the year.

Bel, can you reference where it was said that samples were sent out to a lot more Croda clients? I’m fairly sure we have only been told they had been sent out to the 12 VIP’s from one of the 600 litre batches.

There will be no dog fight between Skinbiotix and Matrixyl, Croda own Matrixyl, so hopefully the fact that they have taken on Skinbiotix tells you all you need to know about it’s efficacy and it’s potential within the market.

There is also a lot of information out there to find from the days when Cath was CEO about how and why Skinbiotix works from a scientific sense, this seems to be what you are looking for. I am not as kind as Toyin so will not serve it up on a plate for you, but it’s all there to find via RNS’s, presentations available on YouTube and the SBTX website. Some of the before/after images of skin barriers are quite compelling.

Oleric, do some proper real life research and you will be surprised what you can find out. I have an anecdotal point which will mean nothing to you but is very real for me. In my town there is a small cosmetic manufacturers. A family run company but they do have a factory with proper blending and packaging machines. They make white label stuff for companies of all sizes, mostly small and very small, but have done some short runs for Unilever. One of the mid-management comes into my workplace, so I asked him what he knew about the lysate. He was aware what I was talking about, and said they do have the ability to purchase ingredients from Croda. That’s my only point, nothing more; that someone in the industry was aware what I was talking about, which I took as a positive. I suppose they will only ever deal with it if they get asked to make a product containing it.

Re the share price action, remember that we are here because we are investors. Most people that come to know about the lysate will be in the industry and will be much more concerned with how they can make money by buying the lysate and putting it into a product than they will be researching it’s source and pouring their hard earned money into an AIM listed small cap whose price has plummeted in the past year. Most that come across the product probably have never bought a share in their life, they don’t think or move like we do. The lysate presents them with a totally different opportunity than it does us.

Time will tell, SA has said some equipment has been made specifically for the lysate to avoid any risk of cross contamination, so that’s what I believe. Whether that is a full production line or just the vessels, I don’t know, and to be honest I don’t need to know. I think the production equipment will be housed with other Croda production equipment so makes the skilled manpower argument a slightly moot point, the factory workers will input their time and expertise running the equipment when they need to in and amongst the production of other ingredients. We know it’s an 18 hour cycle and it should not take constant input, there will be written manufacturing processes that will probably span shifts, as with all the other goings on in Croda’s magic factory of expensive creams and potions.

What we do know is with Croda in charge of the launch, it should be substantially more successful than the Axis launch.

Cheers for taking the time to post the link and referencing the time Toyin, I know you shouldn’t have to but it certainly clears the misinformation up. No offence Bel regarding misinformation I know you are just raising a genuine concern. I think your worries are just born out of a lot of time spent mulling over this investment, I think it’s something a lot of us are guilty of who are heavily exposed here. I know in the new year I’ll be trying to leave the company to do what they say they will and just check in when an RNS is released. I suppose a watched kettle never boils.

All valid and sensible points. Lots of ways to pay for a company, but I do think any method would be combined with the need for liquid cash over and above our running costs. Personally I would take it as a good sign if the current owners of the target took part payment in SBTX shares which would be freshly issued, they will be party to details about plans for their company so it would be a huge positive if they wanted to be a part of it.

Can we also take a second to appreciate that some are worrying about another raise before the cash from the current raise has even hit the bank. How can the board win with that kind of expectation? I’m far from the biggest fan of the current state of play; the share price and the sales progress, but even from my fairly pessimistic position I can see the board need a good prescription of investor patience over the next 3/12 months to make good their ‘strategic’ decisions.